Meddoc
17
2
2
15
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 17 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 15 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (17)
Profylactic Treatment for Patients in Risk Osteoporosis
Role: lead
Validation of Bulbicam Used on Patient Suffering From Diabetes Without Retinopathy
Role: lead
The Long-term Effect of Daily Jarlsberg Cheese Intake in Patient With Osteopenia
Role: lead
Recommended Dose Estimation of BP-C2
Role: lead
Efficacy Comparison of Jarlsberg- and Norvegia Cheese on Bone Markers and Bone Mineral Density in Nordic Skiers
Role: lead
Bulbicam Validation on Glaucoma- and Cataract Patients
Role: lead
Validation of Bulbicam for Parkinson- and Ataxia-patients
Role: lead
Validation of Bulbicam for DR- and AMD-patients
Role: lead
Daily Dose Estimation of Jarlsberg Cheese in Healthy Norwegian Elderly Male and Female
Role: lead
Dose Estimation of Jarlsberg Cheese in Young, Active Norwegian Cross-country Skiers (XCS)
Role: lead
Estimation of a Maintaining Daily Jarlsberg Cheese-dose
Role: lead
Dose-finding Study of BP-C1 in Patients With Stage IV Breast Cancer
Role: collaborator
BP-C1 Monotherapy in Patients With Metastatic Breast Cancer Cancer: Estimation of Optimal Duration of Treatment
Role: collaborator
BP-C1 in Short-term Treatment of Patients With Metastatic Breast Cancer
Role: collaborator
BP-C1 in Short-term Treatment of Thai Patients With Metastatic Breast Cancer
Role: collaborator
BP-C1 in Short-term Treatment of Metastatic Pancreatic Cancer
Role: collaborator
Response Surface Pathway Design With Two Interventional- and One Response Variable in Estimating Minimum Efficacy Dose
Role: lead
All 17 trials loaded